Related Experiment Video
Updated: Sep 28, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Anti-amyloid beta activity of metallothionein-III is different from its neuronal growth inhibitory activity:
Yoshifumi Irie1, Wing Ming Keung
1Department of Psychiatry at Massachusetts Mental Health Center, Harvard Medical School, One Kendall Square, Building 600, 3/F, Cambridge, MA 02139, USA.
Abstract:
Recent studies have shown that metallothionein-III (MT-III), but not MT-I or -II, antagonizes both the neurotrophic and neurotoxic effects of amyloid beta peptides (Abetas). Further, its anti-Abeta-toxicity effect was attributed to the fact that it inhibits the formation of fibrillar Abeta. MT-III alone also affects neuron survival in culture-promoting at low but inhibiting at high concentrations. To characterize these biological activities of MT-III in relation to its neuronal growth inhibitory activity discovered by Uchida et al. [Neuron 7 (1991) 337-347], we here studied effects of the P7S/P9A double mutant, and the N- and C-terminal domains of MT-III on primary cultures of rat embryonic cortical neurons in the presence and absence of Abeta. Results show that (i). only the wild-type MT-III inhibited the formation of SDS-resistant Abeta aggregates and protected cortical neurons from the toxic effect of Abeta, and (ii). both the wild type and the N-terminal domain of MT-III promote neuron survival at low concentrations but inhibited it at high concentrations. On the basis of these findings, we conclude that the anti-Abeta activity of MT-III is different from its neuronal growth inhibitory activity and suggest that the increased trophic activity of AD brain extracts could be attributed to its low MT-III content.

